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Results were similar in the ITT population (HER2+ or HER2- patients). CONCLU-
SIONS: Utility values for patients with HER2+ MBC are generally similar for patients 
receiving letrozole plus lapatinib or letrozole plus placebo. Post-progression utility 
values were based largely on a single assessment for each patient and are may not be 
representative of patient utility during all post-progression survival.
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OBJECTIVES: The determinants of utilities for health are largely unknown. The 
psychosocial construct Locus of control (LOC) describes the extent to which individu-
als feel their health is determined by their actions, by a powerful external ﬁgure, or 
by chance. LOC is associated with health-related quality of life among cancer patients 
but its impact on utilities has not been examined. The objective was to estimate the 
effect of LOC on utilities for head and neck cancer (HNC) health states among 
Canadians without cancer. METHODS: A convenience sample of respondents without 
cancer was recruited according to the age- and sex-distribution of Canada in Vancou-
ver and Toronto. Standard gamble utilities were elicited for health states describing 
HNC stage and type. Standardized health state descriptions were based on literature 
review, trial data, and feedback from clinicians experienced in HNC treatment and 
quality-of-life researchers. Respondents completed the validated Multidimensional 
Health LOC scale. Mixed regression models were used to determine associations 
between interval locus of control scores and utilities, adjusting for demographic 
variables, HNC stage and type. RESULTS: Utility values were elicited from 101 
respondents with a mean age of 47 years (48% male). Mean utilities were: 0.62 for 
locoregional laryngeal, 0.61 for locoregional non-laryngeal, 0.57 for recurrent non-
laryngeal, 0.56 for recurrent laryngeal, 0.52 for metastatic non-laryngeal, 0.50 for 
metastatic laryngeal, and 0.34 for post-progression, HNC. There was suggestive evi-
dence that LOC was associated with utilities (P = 0.079). Respondents who had a 
dominant Chance LOC rated health states signiﬁcant lower (P = 0.012): for every one 
unit increase on the Chance subscale, there was a decrement of 0.011 in mean utility 
value. CONCLUSIONS: This evidence indicates that LOC is a determinant of utilities 
for head and neck cancer health states. Replicating these ﬁndings in other populations 
and diseases would shed insight into the psychosocial determinants of preferences.
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OBJECTIVES: This research is designed to reveal Quality of life of Korean patients 
with metastatic breast cancer for cancer treatments. METHODS: This is a multicenter, 
cross-sectional study in breast cancer patients receiving palliative chemotherapy. Total 
199 patients with metastatic breast cancer were interviewed from 4 centers. Clinical, 
socio-demographic, and quality of life data were collected. Subjects completed a face-
to-face interview with trained interviewer to assess their health status for breast cancer 
treatment. Patients recalled the before diagnosis status under current situation. we 
used the three methods to evaluate the health status; EORTC QLQ-C30, BR-23, 
EQ-5D. RESULTS: Overall utility weights for EORTC QLQ C30 and EQ-5D was 
0.81 and 0.78 respectively(before diagnosis). It is higher than those of current 
(EORTC QLQ-C30: 0.54, EQ-5D: 0.60). the patients who are before diagnosis esti-
mated higher functioning score compared to current. (physical functioning scale; 
before cancer: 92.8, current 65.3) The higher the score is, the better patients’ function 
is. Symptom scale scores are the similar with functioning scale scores. The higher the 
score is, the worse the symptom is. before cancer status has lower symptom scale 
scores than current. (fatigue symptom scale; Before cancer: 25.2, current: 48.5) BR 
23 scale, there were deteriorations in patients for all domains compared to scores of 
before cancer patients. Especially, patient’ current body image score is signiﬁcantly 
lower than that of before diagnosis patients. (before diagnosis: 91.4, current: 46.4) 
CONCLUSIONS: There are few study of Quality of life in breast cancer patients. It 
is meaningful that this study provided the utility weights for breast cancer patients in 
Korea.
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OBJECTIVES: To validate a questionnaire evaluating patient satisfaction with the 
darbepoetin alpha pre-ﬁlled device for self-injection (Aranesp®SureClickTMdevice) and 
the 2care®service for product delivery and helping patients with injection at home. 
METHODS: Patients with non-myeloid malignancies to be treated with 500mcg 
darbepoetin alfa three-weekly for chemotherapy-induced anaemia using the 
Aranesp®SureClickTMdevice and 2care®service were enrolled in a prospective, obser-
vational study in the The Netherlands. Following each of the ﬁrst three darbepoetin 
alpha-injections, patients completed a questionnaire speciﬁcally developed for this 
study. This questionnaire included items (answer ranges, 0–10) related to satisfaction 
with the device (5 items: ease-of-use/pain /anxiety/expectations/overall-satisfaction) 
and the 2care®service (9 items: quickness/delivery/punctuality/friendliness/compe-
tency/ﬂexibility/information/usefulness/overall-satisfaction). Questionnaire structure 
was deﬁned using factor analyses and conﬁrmed by multi-trait analysis. Internal 
consistency was evaluated by Cronbach’s alfa. Ranges of minimal important differ-
ences (MIDs) were calculated using anchor-based and distribution-based methods. 
Determinants of overall satisfaction with the Aranesp®SureClickTMdevice were ana-
lyzed by multiple regression analyses. RESULTS: A total of 283 patients were evalu-
able. At ﬁrst injection, median item-scores ranged from 8.0–9.4. Two composite scores 
were deﬁned (1 item not correlated with any scores: quickness 2care®-contact making 
appointment): satisfaction with the Aranesp®SureClickTMdevice and satisfaction with 
the 2care®service. Item-score correlations ranged from 0.61–0.81 and 0.64–0.79, 
respectively. Cronbach’s alfas were 0.85 and 0.84. All items met convergent and 
discriminant validity criteria. Plausible MIDs were 0.5–0.7 and 0.3 for satisfaction 
with the Aranesp®SureClickTMdevice and 2care®service, respectively. At ﬁrst injec-
tion, satisfaction with the Aranesp®SureClickTMdevice was mainly determined by 
expectations, pain, and ease-of-use. After 3 injections, the main driver was ease-of-use. 
CONCLUSIONS: Patients were satisﬁed with the Aranesp®SureClickTMdevice and 
2care®service. The satisfaction questionnaire showed good dimension structure and 
internal consistency reliability. MIDs were provided for interpretation of scores. 
Determinants of patient satisfaction were shown to change (ease-of-use becoming the 
main driver, while pain importance decreased) while the patient accumulates experi-
ence with the Aranesp®SureClickTMdevice.
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OBJECTIVES: The standard lexicon for reporting adverse events in NCI-sponsored 
trials is the Common Terminology Criteria for Adverse Events (CTCAE), which 
consists of over 800 individual items. Currently, all items are reported by clinicians. 
However, multiple studies have found that clinicians tend to underreport symptom 
severity and onset compared with patient self-reports. In October 2008, the NCI 
contracted a multi-institution consortium to develop patient versions of CTCAE items, 
and an administration electronic platform. METHODS: A multidisciplinary commit-
tee systematically identiﬁed CTCAE items with sufﬁcient subjective component to be 
amenable to patient reporting. Systematic reviews of publications and existing ques-
tionnaires, and analyses of existing data sets were conducted to determine optimal 
formats for questions and response options, and plain-language terms for each new 
“PRO-CTCAE” item. Cognitive interviews were conducted in 100 patients to reﬁne 
items. RESULTS: Seventy-seven “symptoms” were identiﬁed in the CTCAE which 
were amenable to patient reporting. The committee determined that measured attri-
butes for each symptom should include frequency, severity, and activity interference, 
assessed via discrete questions for each symptom. A standardized format for questions 
and response options, and plain language terms for each symptom were formulated. 
A web-based platform was developed for creating and administering the new PRO-
CTCAE items. CONCLUSIONS: A patient version of the CTCAE system, known as 
the PRO-CTCAE, has been developed. This prototype is undergoing further testing 
to assess its validity, reliability, usability, and feasibility for use in a variety of cancer 
care settings. The PRO-CTCAE system both will enhance adverse event reporting by 
directly integrating patient experiences and will foster consistency of data collection 
methods across studies.
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BACKGROUND: Overall survival (OS) has been traditionally used as the primary 
endpoint in oncology trials, however cross-over to 2nd line agents may result in biases 
for OS. Recent trials have used progression free survival (PFS) as the primary endpoint. 
Understanding patient preferences regarding expected PFS vs. avoidance of risk for 
toxicities in medical decision-making is needed. OBJECTIVES: To estimate RCC 
patients’ willingness to accept toxicities and medication-related risks to increase PFS. 
METHODS: US residents aged 18 years and over with RCC completed a web-enabled, 
choice-format conjoint survey that presented a series of 12 trade-off questions, each 
including a pair of hypothetical RCC medication proﬁles. Each proﬁle was deﬁned by 
efﬁcacy (PFS), tolerability effects (fatigue, diarrhea, hand-foot syndrome, mouth 
